Physician profile
Behzad Farah
NPI 1689630915
$680.16
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $505 · 2020: $108 · 2021: $66.36.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $99.41 | 2019 | |
| Pfizer INC. | $76.19 | 2019-2020 | |
| Abbvie INC. | $66.36 | 2021 | |
| Amgen INC. | $59.05 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $56.30 | 2019-2020 | |
| Allergan, INC. | $52.33 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $42.00 | 2019 | |
| Avanir Pharmaceuticals, INC. | $33.61 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $27.03 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $26.51 | 2019 | |
| Janssen Pharmaceuticals, INC | $23.02 | 2019 | |
| Astellas Pharma US INC | $17.34 | 2019 | |
| Sanofi-Aventis U.S. LLC | $16.03 | 2020 | |
| Hologic Sales and Service, LLC | $15.94 | 2019 | |
| Lilly USA, LLC | $14.58 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.53 | 2020 | |
| Glaxosmithkline, LLC. | $14.13 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.50 | 2019 | |
| Concordia Pharmaceuticals INC. | $12.30 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Behzad Farah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.